Matches in SemOpenAlex for { <https://semopenalex.org/work/W4230653860> ?p ?o ?g. }
Showing items 1 to 50 of
50
with 100 items per page.
- W4230653860 endingPage "456" @default.
- W4230653860 startingPage "456" @default.
- W4230653860 abstract "<h3>Abstract</h3> Patients with hematologic malignancies have poor outcomes from COVID infection and are less likely to mount an antibody response after COVID infection. There is limited data on the efficacy of the COVID vaccines in lymphoma patients, and to suggest the optimal timing of vaccination to elicit immunity in patients receiving immunochemotherapy. This is a retrospective study of adult lymphoma patients who received the COVID vaccine between 12/1/2020 and 11/30/2021. The primary endpoint was a positive anti-COVID spike protein antibody titer following the primary COVID vaccination series. The primary series was defined as 2 doses of the COVID mRNA vaccines or 1 dose of the COVID adenovirus vaccine. Subgroups were compared using Fisher’s exact test, and unadjusted and adjusted logistic regression models were used for univariate (UVA) and multivariate (MVA) analyses. A total of 243 patients were included in this study; 72 patients (30%) with indolent lymphomas; 56 patients (23%) with Burkitt’s, diffuse large B-cell lymphoma (DLBCL), and primary mediastinal B-cell lymphoma (PMBL) combined; 55 patients (22%) with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL); and 44 patients (18%) with Hodgkin and T-cell lymphomas (HL/TCL) combined. One-hundred fifty-eight patients (65%) developed anti-COVID spike protein antibodies after completing the primary COVID vaccination series. Thirty-eight of 46 (83%) patients who received an additional primary shot and had resultant levels produced anti-COVID spike protein antibodies. When compared to other lymphoma types, patients with CLL/SLL had a numerically lower seroconversion rate of 51% following the primary series whereas patients with HL/TCL appeared to have a robust antibody response with a seropositivity rate of 77% (p=0.04). Lymphoma patients are capable of mounting a humoral response to the COVID mRNA vaccines. Further studies are required to confirm our findings, including whether T-cell immunity would be of clinical relevance in this patient population." @default.
- W4230653860 created "2022-05-11" @default.
- W4230653860 creator A5022026729 @default.
- W4230653860 creator A5067827714 @default.
- W4230653860 date "1995-08-12" @default.
- W4230653860 modified "2023-09-26" @default.
- W4230653860 title "Authors' reply" @default.
- W4230653860 doi "https://doi.org/10.1136/bmj.311.7002.456" @default.
- W4230653860 hasPublicationYear "1995" @default.
- W4230653860 type Work @default.
- W4230653860 citedByCount "0" @default.
- W4230653860 crossrefType "journal-article" @default.
- W4230653860 hasAuthorship W4230653860A5022026729 @default.
- W4230653860 hasAuthorship W4230653860A5067827714 @default.
- W4230653860 hasConcept C126322002 @default.
- W4230653860 hasConcept C159654299 @default.
- W4230653860 hasConcept C203014093 @default.
- W4230653860 hasConcept C22070199 @default.
- W4230653860 hasConcept C2777938653 @default.
- W4230653860 hasConcept C2778461978 @default.
- W4230653860 hasConcept C2779338263 @default.
- W4230653860 hasConcept C71924100 @default.
- W4230653860 hasConceptScore W4230653860C126322002 @default.
- W4230653860 hasConceptScore W4230653860C159654299 @default.
- W4230653860 hasConceptScore W4230653860C203014093 @default.
- W4230653860 hasConceptScore W4230653860C22070199 @default.
- W4230653860 hasConceptScore W4230653860C2777938653 @default.
- W4230653860 hasConceptScore W4230653860C2778461978 @default.
- W4230653860 hasConceptScore W4230653860C2779338263 @default.
- W4230653860 hasConceptScore W4230653860C71924100 @default.
- W4230653860 hasIssue "7002" @default.
- W4230653860 hasLocation W42306538601 @default.
- W4230653860 hasOpenAccess W4230653860 @default.
- W4230653860 hasPrimaryLocation W42306538601 @default.
- W4230653860 hasRelatedWork W1570084920 @default.
- W4230653860 hasRelatedWork W1977724887 @default.
- W4230653860 hasRelatedWork W1986909167 @default.
- W4230653860 hasRelatedWork W2029074520 @default.
- W4230653860 hasRelatedWork W2063298797 @default.
- W4230653860 hasRelatedWork W2095074781 @default.
- W4230653860 hasRelatedWork W2332968797 @default.
- W4230653860 hasRelatedWork W2409919335 @default.
- W4230653860 hasRelatedWork W2418633411 @default.
- W4230653860 hasRelatedWork W4319815297 @default.
- W4230653860 hasVolume "311" @default.
- W4230653860 isParatext "false" @default.
- W4230653860 isRetracted "false" @default.
- W4230653860 workType "article" @default.